COMPANY

Aptose Biosciences

HQ: Del Mar, CA source · aptose.com ↗ · Canada

Keywords: small molecule oncology hematology cancer Acute Myeloid Leukemia Leukemia, Myeloid, Acute Refractory AML Relapsed Adult AML Myelodysplastic Syndrome With Excess Blasts-2 Chronic Myelomonocytic Leukemia Myelodysplastic Syndromes Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Non-Hodgkin's Lymphoma Acute Myelogenous Leukemia in Relapse Acute Myelogenous Leukemia, Relapsed, Adult Adult Acute Myelogenous Leukemia Acute Myelogenous Leukemia High Risk Myelodysplasia Pancreatic Cancer Renal Cell Carcinoma Neoplasm Metastases CG-806 GTI-2040 APTO-253 LOR-253 Virulizin®

Profile checked Oct 10, 2026

$8.0MRaised (2 yrs)8Trials (company is sponsor)

Timeline

Nov 25, 2024 Raise Follow-on offering: $8M (total, as published), announced Nov 25, 2024. Source: SEC filing. source ↗
Oct 6, 2020 Trial start Phase 1: A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS source ↗
Apr 30, 2019 Trial start Phase 1: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas source ↗
Mar 11, 2019 Trial start Phase 1/Phase 2: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia source ↗
2014-10 Trial start Phase 1: A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS source ↗
2011-01 Trial start Phase 1: A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours source ↗
2007-08 Trial start Phase 2: Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) source ↗
2002-07 Trial start Phase 3: A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic Cancer source ↗
2002-03 Trial start Phase 1/Phase 2: Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma source ↗

Upcoming milestones

2026-11 (ESTIMATED) · Phase 1/Phase 2 · Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia · NCT03850574

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $8.0M. Last 2 years.

Nov 25, 2024 Follow-on offering: $8M (total, as published), announced Nov 25, 2024. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 8

Record	Title	Phase	Status	Start	Primary completion
NCT03850574	Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia	Phase 1/Phase 2	Recruiting	Mar 11, 2019	2026-11 (estimated)
NCT04477291	A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS	Phase 1	Terminated	Oct 6, 2020	Apr 15, 2024 (actual)
NCT03893682	A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas	Phase 1	Terminated	Apr 30, 2019	May 17, 2024 (actual)
NCT02267863	A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS	Phase 1	Terminated	2014-10	2021-09 (actual)
NCT00565058	Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)	Phase 2	Completed	2007-08	2009-09 (actual)
NCT01281592	A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours	Phase 1	Completed	2011-01	2013-07 (actual)
NCT00040092	A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic Cancer	Phase 3	Completed	2002-07	2005-07 (actual)
NCT00056173	Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma	Phase 1/Phase 2	Completed	2002-03	2004-12 (actual)